The study is designed to investigate, in detail, the clinical and molecular effects of secukinumab(Cosentyx) in the treatment of Psoriasis Arthritis.
The investigators will also make use of the fact that secukinumab is to be administering to 20 patients with Psoriatic Arthritis (PsA) and investigate whether there is any relationship between vitamin D status and response to secukinumab.
|Study Type :
||Interventional (Clinical Trial)
|Estimated Enrollment :
||Single Group Assignment
||None (Open Label)
||An Exploration of the Dynamic Interaction Between IL-17, IL-17 Inhibition With (Secukinumab) and Neutrophils in Psoriatic Arthritis in Vitro and ex Vivo With Exploratory Study on the Potential Role of Vitamin D
|Study Start Date :
|Estimated Primary Completion Date :
|Estimated Study Completion Date :
For enrollment please visit www.clinicaltrials.gov